`Case 1:23-cv-00089-TSK Document 97-3 Filed 02/13/24 Page 1of3 PagelD #: 4077
`
`EXHIBIT C
`EXHIBIT C
`
`
`
`Case 1:23-cv-00089-TSK Document 97-3 Filed 02/13/24 Page 2 of 3 PageID #: 4078
`
`From:
`Sent:
`To:
`
`Cc:
`Subject:
`
`
`
`Patel, Priyata <Priyata.Patel@weil.com>
`Monday, February 12, 2024 12:23 PM
`Laura Fairneny; QE - Samsung Bioepis; Sandra K. Law; Chad Taylor; Mike Cottler; Mascherin, Terri L.;
`Fogel, Louis E.; Van Horn, Shaun M.; Robert Cerwinski; Andrew Robey; Carl Shaffer; Max Gottlieb;
`mhissam@hfdrlaw.com; Bryant J. Spann; M. David Griffith Jr.; DG-Aflibercept
`Eylea Biosimilars; Eylea; REGENERON PATENT; drpogue@cdkrlaw.com; sruby@cdkrlaw.com
`RE: Regeneron PI Declarants - Deposition Scheduling
`
`[EXTERNAL EMAIL from priyata.patel@weil.com]
`
`Counsel, further to the below, please advise whether Dr. Gross will be deposed on either March 8 (option 1) or April 25
`(option 2).
`
`From: Patel, Priyata <Priyata.Patel@weil.com>
`Sent: Monday, February 12, 2024 11:12 AM
`To: laurafairneny@quinnemanuel.com; QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; Sandra K. Law
`<skl@schraderlaw.com>; Chad Taylor <clt@simmermanlaw.com>; Mike Cottler <mcottler@geminilaw.com>; Mascherin,
`Terri L. <TMascherin@jenner.com>; Fogel, Louis E. <LFogel@jenner.com>; Van Horn, Shaun M.
`<SVanHorn@jenner.com>; Robert Cerwinski <rcerwinski@geminilaw.com>; Andrew Robey <arobey@hfdrlaw.com>; Carl
`Shaffer <cshaffer@hfdrlaw.com>; Max Gottlieb <mgottlieb@hfdrlaw.com>; mhissam@hfdrlaw.com; Bryant J. Spann
`<BSpann@tcspllc.com>; M. David Griffith Jr. <DGriffith@tcspllc.com>; DG-Aflibercept <DG-
`Aflibercept@NETORG8512690.onmicrosoft.com>
`Cc: Eylea Biosimilars <Eylea.Biosimilars@weil.com>; Eylea <Eylea@wc.com>; REGENERON PATENT
`<REGENERONPATENT@lists.kellogghansen.com>; drpogue@cdkrlaw.com; sruby@cdkrlaw.com
`Subject: Regeneron PI Declarants - Deposition Scheduling
`
`Counsel,
`
`
`Consistent with the Court’s scheduling order, Regeneron will make its PI declarants available in the United States for a 1-
`day deposition across all four cases. Despite Regeneron’s multiple requests and attempts at compromise, the
`defendants have not narrowed or provided any details regarding their anticipated invalidity defenses. Therefore,
`Regeneron expects to file reply declarations from certain of its witnesses. So that we may reserve appropriate dates
`with the witnesses, please indicate whether defendants will choose to depose such witnesses either: (1) before March
`13 on their opening declarations (option 1) or (2) between April 18 and May 2 on both their opening and reply
`declarations (option 2).
`
`
`Sincerely,
`Priya
`
`
`Option 1
`Declarant
`Bernhardt Trout February 29
`Ranjit Singh
`March 8
`Sean Sheridan March 13
`
`Location
`Option 2
`April 26 Weil’s Boston Office
`April 23 W&C’s DC Office
`April 26
`TBD
`
`
`
`
`
`
`1
`
`
`
`Case 1:23-cv-00089-TSK Document 97-3 Filed 02/13/24 Page 3 of 3 PageID #: 4079
`
`
`Priyata Y. Patel
`Pronouns: She/her/hers
`
`Weil, Gotshal & Manges LLP
`2001 M Street NW, Suite 600
`Washington, DC 20036
`priyata.patel@weil.com
`+1 574 606 7314 Cell
`+1 202 682 7041 Direct
`+1 202 857 0940 Fax
`
`
`
`
`The information contained in this email message is intended only for use of the individual or entity named above. If the
`reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended
`recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly
`prohibited. If you have received this communication in error, please immediately notify us by email, postmaster@weil.com,
`and destroy the original message. Thank you.
`
`2
`
`